📊 AEMD Key Takeaways
Is Aethlon Medical Inc. (AEMD) a Good Investment?
Aethlon Medical is in severe financial distress with minimal revenue generation ($97.1K) while burning significant cash (-$5.2M operating cash flow). The company is unprofitable with negative net margins exceeding -5400%, operating margins of -5523%, and deteriorating returns on equity (-78.5%) and assets (-65.4%). Despite adequate liquidity currently, the company's burn rate will exhaust cash reserves within 16 months without revenue acceleration or capital injection.
Aethlon Medical’s fundamentals are very weak: revenue is negligible relative to its cost base, operating and net losses are extremely large, and free cash flow is deeply negative. While the balance sheet is currently supported by high cash balances, strong liquidity, and no meaningful debt, the business lacks evidence of durable revenue generation and remains dependent on cash consumption rather than operating traction.
Aethlon Medical Inc. Key Strengths (AEMD)
- Strong liquidity position with cash-to-assets ratio of 86% and current ratio of 5.68x
- Zero long-term debt provides financial flexibility and no refinancing risk
- Minimal capital expenditure requirements suggest asset-light business model
- Strong near-term liquidity with $6.96M in cash and a 5.68x current ratio
- Low financial leverage with essentially no long-term debt
- Positive equity base of $6.71M provides some balance-sheet cushion
AEMD Stock Risks: Aethlon Medical Inc. Investment Risks
- Critical revenue shortfall with only $97.1K in annual revenue indicating failed market traction or commercialization
- Severe cash burn of $5.2M annually will deplete $7.0M cash reserves in approximately 16 months without intervention
- Deeply unprofitable operations with -$11.01 diluted EPS and no clear path to profitability based on current business execution
- Negative returns on equity (-78.5%) and assets (-65.4%) indicate shareholder capital destruction
- Operating losses of -$5.4M dwarf minimal revenue, suggesting fundamental business model failure
- Revenue base is extremely small at $97.13K versus $5.27M net loss, indicating poor commercial scale
- Operating cash burn of $5.25M materially pressures runway if revenue does not improve
- Margins, ROA, and ROE are deeply negative, signaling weak growth quality and poor capital efficiency
Key Metrics to Watch
- Quarterly revenue growth and pipeline development indicators
- Monthly cash burn rate and runway remaining before capital depletion
- Operating expense reduction initiatives and path to cash flow breakeven
- Clinical trial progress or FDA approvals for core therapeutic platforms
- Insider trading activity pattern and confidence signals from management
- Quarterly revenue growth and evidence of commercial adoption
- Operating cash burn relative to cash balance
Aethlon Medical Inc. (AEMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.68x current ratio provides a solid financial cushion.
AEMD Profit Margin, ROE & Profitability Analysis
AEMD vs Healthcare Sector: How Aethlon Medical Inc. Compares
How Aethlon Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aethlon Medical Inc. Stock Overvalued? AEMD Valuation Analysis 2026
Based on fundamental analysis, Aethlon Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aethlon Medical Inc. Balance Sheet: AEMD Debt, Cash & Liquidity
AEMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aethlon Medical Inc.'s revenue has declined by 12% over the 5-year period, indicating business contraction. The most recent EPS of $-38.87 indicates the company is currently unprofitable.
AEMD Revenue Growth, EPS Growth & YoY Performance
AEMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$2.0M | $-0.12 |
| Q1 2023 | N/A | -$2.1M | $-0.14 |
| Q3 2022 | $17.1K | -$1.4M | N/A |
| Q2 2022 | N/A | -$1.4M | $-0.13 |
| Q3 2021 | $413.5K | -$819.6K | N/A |
| Q2 2021 | N/A | -$1.4M | N/A |
| Q1 2021 | N/A | -$1.4M | N/A |
| Q3 2020 | N/A | -$819.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aethlon Medical Inc. Dividends, Buybacks & Capital Allocation
AEMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aethlon Medical Inc. (CIK: 0000882291)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AEMD
What is the AI rating for AEMD?
Aethlon Medical Inc. (AEMD) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AEMD's key strengths?
Claude: Strong liquidity position with cash-to-assets ratio of 86% and current ratio of 5.68x. Zero long-term debt provides financial flexibility and no refinancing risk. ChatGPT: Strong near-term liquidity with $6.96M in cash and a 5.68x current ratio. Low financial leverage with essentially no long-term debt.
What are the risks of investing in AEMD?
Claude: Critical revenue shortfall with only $97.1K in annual revenue indicating failed market traction or commercialization. Severe cash burn of $5.2M annually will deplete $7.0M cash reserves in approximately 16 months without intervention. ChatGPT: Revenue base is extremely small at $97.13K versus $5.27M net loss, indicating poor commercial scale. Operating cash burn of $5.25M materially pressures runway if revenue does not improve.
What is AEMD's revenue and growth?
Aethlon Medical Inc. reported revenue of $97.1K.
Does AEMD pay dividends?
Aethlon Medical Inc. does not currently pay dividends.
Where can I find AEMD SEC filings?
Official SEC filings for Aethlon Medical Inc. (CIK: 0000882291) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AEMD's EPS?
Aethlon Medical Inc. has a diluted EPS of $-11.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AEMD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aethlon Medical Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AEMD stock overvalued or undervalued?
Valuation metrics for AEMD: ROE of -78.5% (sector avg: 15%), net margin of -5,422.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AEMD's AI grade for 2026?
Our dual AI analysis gives Aethlon Medical Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AEMD's free cash flow?
Aethlon Medical Inc.'s operating cash flow is $-5.2M, with capital expenditures of $1.7K. FCF margin is -5,404.7%.
How does AEMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,422.7% (avg: 12%), ROE -78.5% (avg: 15%), current ratio 5.68 (avg: 2).